Interleukin Genetics Report issue

For profit
Founded: Waltham MA United States (1997)
Status: Acquired by ORIG3N (2017)

Organization Overview

First Clinical Trial
2004
NCT00303238
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 4